Get the Stockscreener App
4.19
2.33%
-0.10
After Hours:
4.09
-0.10
-2.39%
Briacell Therapeutics Corp stock is traded at $4.19, with a volume of 208.86K.
It is down -2.33% in the last 24 hours and down -6.26% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$4.29
Open:
$4.22
24h Volume:
208.86K
Relative Volume:
0.33
Market Cap:
$16.25M
Revenue:
-
Net Income/Loss:
$-16.60M
P/E Ratio:
-4.7079
EPS:
-0.89
Net Cash Flow:
$-23.48M
1W Performance:
-4.34%
1M Performance:
-6.26%
6M Performance:
-64.92%
1Y Performance:
-86.17%
1-Day Range:
$3.99
$4.35
1-Week Range:
$3.75
$4.6701
52-Week Range:
$3.09
$36.60
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
4.19 | 16.25M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
(BCT) Pivots Trading Plans and Risk Controls (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics (BCTX) Sees Stock Boost On Promising Trial News - Stocks Telegraph
In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II - insights.citeline.com
BriaCell Stock Rises On Positive Survival Data From Study In Cancer Patients: Retail Gets More Bullish - NewsBreak: Local News & Alerts
BriaCell Therapeutics Corp. - Baystreet.ca
BCTXBriacell Therapeutics Corp Latest Stock News & Market Updates - Stock Titan
BriaCell therapy improves breast cancer survival rate | 2025-04-16 | Investing News - Stockhouse
BriaCell (BCTX) Reports Promising Phase 2 Survival Data in Breas - GuruFocus
BriaCell Says Breast Cancer Therapy Shows Positive Survival Data; Shares Rise - marketscreener.com
BriaCell (BCTX) Reports Promising Phase 2 Survival Data in Breast Cancer Study | BCTX Stock News - GuruFocus
BriaCell’s Phase 2 Study Shows Promising Survival Data in Breast Cancer - TipRanks
BriaCell reports survival boost in breast cancer study - Investing.com
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer - GlobeNewswire
Clinical Trial Success: BriaCell's Treatment Outperforms Standard Therapy in Advanced Breast Cancer - Stock Titan
(BCT) Investment Report (BCT:CA) - news.stocktradersdaily.com
(BCT) Optimized Trading Opportunities (BCT:CA) - news.stocktradersdaily.com
Briapro Therapeutics develops anti-B7-H3 antibodies - BioWorld MedTech
BriaPro Advances Novel Anti-Cancer Antibody Development - TipRanks
BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3 - GlobeNewswire
Game-Changing Cancer Treatment: BriaCell's New Antibodies Target Multiple Solid Tumors - Stock Titan
Virtu Financial LLC Makes New $27,000 Investment in BriaCell Therapeutics Corp. (NASDAQ:BCTX) - Defense World
BriaCell Therapeutics (OTCMKTS:BCTXF) Shares Up 4% – Here’s What Happened - Defense World
BriaCell Therapeutics (NASDAQ:BCTX) Trading 4% Higher – Time to Buy? - Defense World
(BCT) Technical Patterns and Signals (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT) - The Globe and Mail
BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Short Interest Update - Defense World
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference - GlobeNewswire
BriaCell to Showcase Cancer Immunotherapy Advances at AACR 2025 - TipRanks
New Clinical Data: BriaCell's Registration Trial Results for Advanced Breast Cancer Treatment - Stock Titan
Where Will Rigetti Computing Stock Be in 1 Year? - The Globe and Mail
Dan Ives Is Pounding the Table on Microsoft Stock. Should You Buy the Dip? - The Globe and Mail
Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? - The Globe and Mail
(BCT) Stock Evaluation Report (BCT:CA) - Stock Traders Daily
(BCT) Market Dynamics and Trading Signals (BCT:CA) - news.stocktradersdaily.com
What To Expect From Carnival’s (CCL) Q1 Earnings - The Globe and Mail
BriaCell’s Phase 3 Breast Cancer Trial Proceeds After Safety Review By Investing.com - Investing.com South Africa
Stocks In Play: BriaCell Therapeutics Corp By Baystreet.ca - Investing.com Canada
(BCT) Technical Analysis and Trading Signals (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Corp - Baystreet.ca
Stocks in play: BriaCell Therapeutics Corp - The Globe and Mail
BriaCell Therapeutics Says Data Safety Monitoring Board Recommends Continuation of Phase 3 Trial in Metastatic Breast Cancer - MarketScreener
BriaCell’s Phase 3 Metastatic Breast Cancer Study Receives Positive DSMB Review - TipRanks
BriaCell’s Phase 3 Breast Cancer Trial Proceeds After Safety Review - Investing.com
Second Data Safety Monitoring Board Issues Positive - GlobeNewswire
Major Milestone: BriaCell's Breast Cancer Immunotherapy Passes Critical Safety Review in Phase 3 Trial - Stock Titan
3 Reasons DRS is Risky and 1 Stock to Buy Instead - The Globe and Mail
Briacell Therapeutics Corp reports results for the quarter ended January 31Earnings Summary - TradingView
BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Growth in Short Interest - Defense World
Briacell Therapeutics Corp expected to post a loss of $1.12 a shareEarnings Preview - TradingView
3 Industrials Stocks Walking a Fine Line - The Globe and Mail
BriaCell Therapeutics (OTCMKTS:BCTXF) Trading 0.3% Higher – Here’s Why - Defense World
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):